Literature DB >> 12895214

Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis.

C K Rayner1, G McCormack, A V Emmanuel, M A Kamm.   

Abstract

BACKGROUND: Intravenous ciclosporin for acute, severe colitis is usually administered in a dose of 4 mg/kg/day, with concurrent intravenous steroids. This is associated with considerable morbidity. We have been using a low-dose regimen, most commonly without concurrent steroids, for seven years, and present the outcome.
METHODS: Records of all patients admitted for severe ulcerative colitis, treated by one physician over seven years, were reviewed.
RESULTS: Thirty-one patients received low-dose intravenous ciclosporin (2 mg/kg/day) for a median 8 days. Eleven early patients received concurrent intravenous corticosteroids. Three patients had hypertension requiring dose reduction, one elevated creatinine and one elevated liver enzymes (all transient), and four experienced infection (two arm cellulitis, one perianal abscess, one post-operative wound infection). Twenty-four patients (77%) avoided urgent colectomy, and were discharged on oral ciclosporin and azathioprine. After a median 18 months (range 3-77), 14 patients (45% of total) avoided colectomy, of whom eight had flares responding to medical therapy and two had persistent, mildly active disease.
CONCLUSIONS: Low-dose intravenous ciclosporin (2 mg/kg/day), usually used as a monotherapy and followed by azathioprine, achieves similar long-term efficacy to higher dose ciclosporin combined with steroids in severe acute ulcerative colitis. Morbidity appears to be low.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12895214     DOI: 10.1046/j.1365-2036.2003.01618.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  14 in total

1.  Antagonist: Early surgical intervention in ulcerative colitis.

Authors:  M A Kamm
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

2.  Cytapheresis in patients with severe ulcerative colitis after failure of intravenous corticosteroid: a long-term retrospective cohort study.

Authors:  Ken Fukunaga; Kazuko Nagase; Takeshi Kusaka; Nobuyuki Hida; Yoshio Ohda; Koji Yoshida; Katsuyuki Tozawa; Koji Kamikozuru; M Iimuro; Shiro Nakamura; Hiroto Miwa; Takayuki Matsumoto
Journal:  Gut Liver       Date:  2009-03-31       Impact factor: 4.519

3.  Ulcerative colitis: current treatment strategies and future prospects.

Authors:  Sagar Garud; Mark A Peppercorn
Journal:  Therap Adv Gastroenterol       Date:  2009-03       Impact factor: 4.409

4.  Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis.

Authors:  Mitsuki Miyata; Kunio Kasugai; Tetsuya Ishikawa; Shinichi Kakumu; Masafumi Onishi; Takeshi Mori
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

Review 5.  Management of acute severe ulcerative colitis.

Authors:  Saurabh Kedia; Vineet Ahuja; Rakesh Tandon
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

6.  Pros and cons of medical management of ulcerative colitis.

Authors:  Udayakumar Navaneethan; Bo Shen
Journal:  Clin Colon Rectal Surg       Date:  2010-12

7.  Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy.

Authors:  Parita Patel; Andres Yarur; Sushila Dalal; Atsuhi Sakuraba; David T Rubin; Stephen B Hanauer; Ira Hanan; Laura H Raffals; Russell D Cohen; Joel Pekow
Journal:  Inflamm Bowel Dis       Date:  2018-05-18       Impact factor: 5.325

Review 8.  Treatment of inflammatory bowel disease: a review of medical therapy.

Authors:  Patricia L Kozuch; Stephen B Hanauer
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

Review 9.  Emerging drugs for the treatment of ulcerative colitis.

Authors:  Luca Pastorelli; Theresa T Pizarro; Fabio Cominelli; Maurizio Vecchi
Journal:  Expert Opin Emerg Drugs       Date:  2009-09       Impact factor: 4.191

Review 10.  Hepatic manifestations of non-steroidal inflammatory bowel disease therapy.

Authors:  Robert Hirten; Keith Sultan; Ashby Thomas; David E Bernstein
Journal:  World J Hepatol       Date:  2015-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.